ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Significance of the Phase III FLAURA Study in EGFR+ NSCLC

Joshua Bauml, MD
Published Online: 3:30 PM, Mon September 11, 2017


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.